Extended Analysis Reveals Promising Patterns of Response to 200 Mg Linvoseltamab in Relapsed/Refractory Multiple Myeloma Patients – Linker-MM1 Study Follow-Up
Dr. Hans Lee discusses follow-up to the Linker-MM1 trial, which studied the safety and efficacy of linvoseltamab in relapsed/refractory multiple myeloma.
Abstract Title:
Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Stud Presented at ASH 2023
What is the purpose of this trial?
The purpose of this trial was to investigate the effectiveness and safety of linvoseltamab, a special kind of antibody designed to target B-cell maturation antigen (BCMA) and CD3, in treating relapsed/refractory multiple myeloma (RRMM). The initial findings showed promising results in terms of efficacy and manageable safety. In this report, researchers provide further analysis, focusing on the treatment's effectiveness over time, including the patterns of patient response, and delve into the safety aspects of linvoseltamab. This additional analysis aims to enhance our understanding of the therapy's performance in patients with RRMM.
In this video:
Dr. Hans Lee, MD (The University of Texas MD Anderson Cancer Center — Houston, TX) discusses the follow-up to the Linker-MM1 trial, which studied the safety and efficacy of linvoseltamab in relapsed/refractory multiple myeloma.
Conclusion:
From the abstract: “Linvoseltamab 200 mg induced deep responses in patients with RRMM including those with high-risk myeloma and high tumor burden, and deepened responses over time while maintaining a generally manageable safety profile. More mature data with longer follow-up will be reported at the meeting.”
Trial Information: Abstract #4746
Doctor Bio:
Dr. Hans Lee is an Associate Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. He received his MD from Indiana University. Subsequently, he completed his internal medicine residency training at Washington University in St. Louis, followed by a hematology/oncology fellowship at MD Anderson Cancer Center.
Dr. Lee's clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma. Specifically, his primary research goals are directed towards developing novel approaches to treat multiple myeloma through early phase investigator-initiated and industry-sponsored clinical trials with a strong translational emphasis to interrogate myeloma pathobiology and mechanisms of drug response and resistance. Dr. Lee’s research has been funded by the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the Leukemia and Lymphoma Society (LLS), and has published his work in a number of peer-reviewed journals including the New England Journal of Medicine, Lancet Oncology, Blood, and Leukemia.
